BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

845 related articles for article (PubMed ID: 30922101)

  • 1. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
    Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
    Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression.
    Phillips JL; Norris S; Talbot J; Hatchard T; Ortiz A; Birmingham M; Owoeye O; Batten LA; Blier P
    Neuropsychopharmacology; 2020 Mar; 45(4):606-612. PubMed ID: 31759333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
    Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
    Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression.
    Shiroma PR; Thuras P; Wels J; Albott CS; Erbes C; Tye S; Lim KO
    Transl Psychiatry; 2020 Jun; 10(1):206. PubMed ID: 32591498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
    Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
    Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression.
    de la Salle S; Phillips JL; Blier P; Knott V
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Apr; 115():110507. PubMed ID: 34971723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
    Singh JB; Fedgchin M; Daly EJ; De Boer P; Cooper K; Lim P; Pinter C; Murrough JW; Sanacora G; Shelton RC; Kurian B; Winokur A; Fava M; Manji H; Drevets WC; Van Nueten L
    Am J Psychiatry; 2016 Aug; 173(8):816-26. PubMed ID: 27056608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disentangling the association of depression on the anti-fatigue effects of ketamine.
    Saligan LN; Farmer C; Ballard ED; Kadriu B; Zarate CA
    J Affect Disord; 2019 Feb; 244():42-45. PubMed ID: 30312839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
    Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
    J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
    Murrough JW; Perez AM; Pillemer S; Stern J; Parides MK; aan het Rot M; Collins KA; Mathew SJ; Charney DS; Iosifescu DV
    Biol Psychiatry; 2013 Aug; 74(4):250-6. PubMed ID: 22840761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes in the biomarkers of ketamine (Bio-K) study of open-label IV ketamine for refractory depression.
    Parikh SV; Vande Voort JL; Yocum AK; Achtyes E; Goes FS; Nykamp L; Singh B; Lopez-Vives D; Sera CE; Maixner D; Tarnal V; Severe J; Bartek S; Tye SJ; Rico J; Stoppel CJ; Becerra A; Smart L; Miller CR; Frye MA; Greden JF; Bobo WV
    J Affect Disord; 2024 Mar; 348():143-151. PubMed ID: 38142892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: A protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans.
    Zhuo C; Tian H; Li G; Chen M; Jiang D; Lin X; Xu Y; Wang W
    Brain Behav; 2019 Nov; 9(11):e01423. PubMed ID: 31617335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression.
    George D; Gálvez V; Martin D; Kumar D; Leyden J; Hadzi-Pavlovic D; Harper S; Brodaty H; Glue P; Taylor R; Mitchell PB; Loo CK
    Am J Geriatr Psychiatry; 2017 Nov; 25(11):1199-1209. PubMed ID: 28739263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study.
    Domany Y; Bleich-Cohen M; Tarrasch R; Meidan R; Litvak-Lazar O; Stoppleman N; Schreiber S; Bloch M; Hendler T; Sharon H
    Br J Psychiatry; 2019 Jan; 214(1):20-26. PubMed ID: 30246667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study.
    Ionescu DF; Swee MB; Pavone KJ; Taylor N; Akeju O; Baer L; Nyer M; Cassano P; Mischoulon D; Alpert JE; Brown EN; Nock MK; Fava M; Cusin C
    J Clin Psychiatry; 2016 Jun; 77(6):e719-25. PubMed ID: 27232360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Objective and Subjective Cognitive Function in Patients With Treatment-Resistant Depression Undergoing Repeated Ketamine Infusions.
    Phillips JL; Van Geel A; Burhunduli P; Vasudev D; Batten LA; Norris S; Talbot J; Ortiz A; Owoeye O; Blier P
    Int J Neuropsychopharmacol; 2022 Dec; 25(12):992-1002. PubMed ID: 35931041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
    Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
    Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder.
    Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
    J Psychopharmacol; 2019 Apr; 33(4):494-501. PubMed ID: 30789302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
    aan het Rot M; Collins KA; Murrough JW; Perez AM; Reich DL; Charney DS; Mathew SJ
    Biol Psychiatry; 2010 Jan; 67(2):139-45. PubMed ID: 19897179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.